As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Odyssey Therapeutics Inc. The largest reported stake is Fmr LLC's, at 13%. 7 filings are on record since May 15, 2026 (Schedule 13G/A, November 5, 2026).
Sell to companies like Odyssey Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 6,239,231 · Shared voting: 0 · Sole dispositive: 6,239,237 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Holder: Fmr LLC · Percent: 10.2% · SCHEDULE 13G
- · Holder: SR One Capital Management, LLC · Percent: 8% · SCHEDULE 13D
- · Holder: Tpg Gp A, LLC · Percent: 7.8% · SCHEDULE 13D
- · Holder: Lightspeed Venture Partners XV-B (Ignite), L.P. · Percent: 7.6% · SCHEDULE 13G
Odyssey Therapeutics Inc has 7 Schedule 13D or 13G filings on record since 2026-05-15. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 13% | 6,239,237 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| SR One Capital Management, LLC | 8% | 3,794,883 | SCHEDULE 13D, 2026-05-18 | 2026-05-11 |
| Jeito II S.L.P. | 7.8% | 3,690,145 | SCHEDULE 13D, 2026-05-15 | 2026-05-08 |
| Tpg Gp A, LLC | 7.8% | 3,690,146 | SCHEDULE 13D, 2026-05-18 | 2026-05-11 |
| Lightspeed Venture Partners XV-B (Ignite), L.P. | 7.6% | 3,608,443 | SCHEDULE 13G, 2026-05-18 | 2026-05-11 |
| Dimension Capital II, L.P. | 7.1% | 3,333,516 | SCHEDULE 13D, 2026-05-15 | 2026-05-08 |
Holding shares or following this stake? See who's behind Odyssey Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Odyssey Therapeutics Inc and the records around it.
The people at Odyssey Therapeutics Inc
- Shelley Chu is also named on 1 other Form D filing: Antares Therapeutics, Inc. (May 2025)
Odyssey Therapeutics Inc elsewhere on the record
- IPO filing May 2026
- Form D filing Dec 2025
- Who owns it
Companies that share a holder
- SR One Capital Management, LLC also filed stake reports on 6 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Zenas BioPharma, Inc. (Aug 2026), Veradermics, Inc. (Aug 2026)
- TPG GP A, LLC also filed stake reports on 15 other companies: Allogene Therapeutics, Inc. (Sep 2026), TPG Inc. (Aug 2026), Ceribell, Inc. (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Odyssey Therapeutics Inc
Get an email when Odyssey Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Odyssey Therapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Odyssey Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Odyssey Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 6,239,231 | 0 | 6,239,237 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 6,239,237 | 0 | SCHEDULE 13G/A, 2026-11-05 |
The latest filing identifies Odyssey Therapeutics Inc by CUSIP 67613T104 and gives its principal executive office as 51 SLEEPER STREET, BOSTON, MA 02210 (SCHEDULE 13G/A, 2026-11-05).
Purpose of Transaction (Item 4)
Jeito II S.L.P.
Jeito II S.L.P. acquired the shares of common stock as described in this Schedule 13D for investment purposes in the regular course of its business. Jeito Capital SAS, as the management company of Jeito II S.L.P., may be deemed to be a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Act"), of any securities held by Jeito II S.L.P. Rafaele Tordjman, as Chief Executive Officer of Jeito Capital SAS, and Sabine Dandiguian, as Managing Director of Jeito Capital SAS, may be deemed to be beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by Jeito Capital SAS. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on market conditions, liquidity requirements, the continuing evaluation of the business and prospects of the Issuer and other factors, the Reporting Persons may dispose of or acquire additional shares of common stock of the Issuer. Ksenija Pavletic, who is the General Partner and Chief Commercial Officer at Jeito Capital SAS, is a director of the Issuer. The Reporting Persons, either directly or indirectly through Ms. Pavletic, may engage in discussions from time to time with the Board, the Issuer's management or the Issuer's other stockholders, including discussions that may relate to the items described in clauses (a) through (j) of Item 4 of Schedule 13D. Except as set forth in this Item 4 or Item 6 below, …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-15; the filing has the rest
Dimension Capital II, L.P.
The Reporting Persons acquired the Common Stock set forth in this Schedule 13D and hold their shares of Common Stock for investment purposes. Nan Li currently serves as a member of the Issuer's Board of Directors. Each Reporting Person expects to continuously review such person's investment in the Issuer and, depending on various factors including but not limited to, the price of the Common Stock, the terms and conditions of the transaction, prevailing market conditions and such other considerations as such Reporting Person deems relevant, may at any time or from time to time, and subject to any required regulatory approvals, acquire additional Common Stock, preferred stock or other securities convertible into or exercisable or exchangeable for Common Stock from time to time on the open market, in privately negotiated transactions, directly from the Issuer, or upon the exercise or conversion of securities convertible into or exercisable or exchangeable for Common Stock. Each Reporting Person also may, at any time, subject to compliance with applicable securities laws and regulatory requirements dispose of or distribute some or all of its Common Stock or such other securities as it owns or may subsequently acquire depending on various factors, including but not limited to, the price of the shares, the terms and conditions of the transaction and prevailing market conditions, as well as the liquidity and diversification objectives. Consistent with their investment intent, …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-15; the filing has the rest
SR One Capital Management, LLC
The Funds acquired their respective shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, the Funds and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-18; the filing has the rest
Tpg Gp A, LLC
The information set forth in or incorporated by reference in Items 2, 3, 5 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Share Purchase Agreement TPG Orazio II entered into a Share Purchase Agreement (the "Share Purchase Agreement") with the Issuer, dated as of May 7, 2026, pursuant to which it agreed to purchase, and the Issuer agreed to sell, $25,000,002 in shares of Common Stock at the $18.00 price per share of Common Stock at which shares were sold to the public in the Issuer's initial public offering (the "Concurrent Private Placement"). On May 11, 2026, the Concurrent Private Placement closed (the "Closing"), with the Issuer issuing to TPG Orazio II 1,388,889 shares of Common Stock. The aggregate purchase price of $25,000,002 paid by TPG Orazio II for the shares of Common Stock was funded by equity contributions of the limited partners of TPG Orazio II. Investors' Rights Agreement The TPG Funds entered into an Amended and Restated Investors' Rights Agreement (the "Investors' Rights Agreement") with the Issuer, dated as of June 16, 2025, providing for the registration under the Securities Act of 1933, as amended, for resale of the shares of Common Stock issued at Closing. Other than as described above, none of the Reporting Persons nor, to the best knowledge of each of the Reporting Persons, without independent verification, any of the TPG GP A Officers, currently has any plans or proposals that relate to, or would …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-18; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-05-15 | Jeito II S.L.P. | 7.8% | SCHEDULE 13D |
| 2026-05-15 | Dimension Capital II, L.P. | 7.1% | SCHEDULE 13D |
| 2026-05-18 | SR One Capital Management, LLC | 8% | SCHEDULE 13D |
| 2026-05-18 | Tpg Gp A, LLC | 7.8% | SCHEDULE 13D |
| 2026-05-18 | Lightspeed Venture Partners XV-B (Ignite), L.P. | 7.6% | SCHEDULE 13G |
| 2026-06-05 | Fmr LLC | 10.2% | SCHEDULE 13G |
| 2026-11-05 | Fmr LLC | 13% | SCHEDULE 13G/A |
Questions about who owns Odyssey Therapeutics Inc
Who owns Odyssey Therapeutics Inc?
On this page, 6 holders' latest ownership filings report 5% or more of Odyssey Therapeutics Inc: Fmr LLC (13%, Schedule 13G/A, filed 2026-11-05), SR One Capital Management, LLC (8%, Schedule 13D, filed 2026-05-18), Jeito II S.L.P. (7.8%, Schedule 13D, filed 2026-05-15), Tpg Gp A, LLC (7.8%, Schedule 13D, filed 2026-05-18) and Lightspeed Venture Partners XV-B (Ignite), L.P. (7.6%, Schedule 13G, filed 2026-05-18); 1 more is listed above.
Who are the largest shareholders of Odyssey Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Odyssey Therapeutics Inc on this page are Fmr LLC (13%), SR One Capital Management, LLC (8%) and Jeito II S.L.P. (7.8%).
When did Fmr LLC buy into Odyssey Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-06-05, reporting 10.2%; its latest, Schedule 13G/A filed 2026-11-05, reports 13%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Odyssey Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 8, 2026 | IPO filing, Form 424B4 | $18 a share | IPO filings | Source |
| May 4, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| April 17, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| December 4, 2025 | Form D, private offering | $214.03M sold | Form D page | Source |
| June 9, 2025 | IPO filing, Form RW | — | IPO filings | Source |
| January 17, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Odyssey Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.